BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sulfasalazine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sulfasalazine\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05703425-3026@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sulfasalazine: Phase 2 readout est. (NCT05703425)
DESCRIPTION:Sulfasalazine\, phase 2.\nStudy: The Effect of Sulfasalazine on
  CRH Levels in Pregnant Women\nEstimated primary completion: 31 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sulfasalazine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0570342
 5
URL:https://assetmemo.bio/drug/sulfasalazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293378-3026@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Sulfasalazine: Phase na readout est. (NCT06293378)
DESCRIPTION:Sulfasalazine\, phase na.\nStudy: Safety and Effectiveness of S
 ulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.\nEstimated prim
 ary completion: 10 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sulfasalazine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06293378
URL:https://assetmemo.bio/drug/sulfasalazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
